- Email: [email protected]
Associated conditions with statin-induced muscle adverse effects
e198
Abstracts / Atherosclerosis 241 (2015) e149ee229
EAS-0234. ASSOCIATED CONDITIONS WITH STATIN-INDUCED MUSCLE ADVERSE EFFECTS ~ ez-Corte s 2, J.A. Flores 3, J. Rius 4. 1 Lipids Unit, J. Pedro-Botet 1, *, J. Mill an Nún Hospital del Mar, Barcelona, Spain; 2 Internal Medicine, HGU Gregorio ~o n, Madrid, Spain; 3 Endocrinology, Hospital del Mar, Barcelona, Maran Spain; 4 Medical Affairs, Esteve, Barcelona, Spain
* Corresponding author. Theclinical spectrum of statin induced myotoxicity includes clinical symptoms, signs and laboratory findings, fromasymptomatic elevation of CK levels or benign myalgia toa more severe painful myositis and fatal rhabdomyolysis. The aim ofthis study was to describe the severity of muscle injury and associatedconditions related with statin therapy and to identify patients that may have potential interactions withstatins Thismulticenter national study including statin-treated patients of both sexes over18 years of age with on-visit recorded for evaluation including: age, gender,anthropometric parameters, cardiovascular risk factors (dyslipidemia,hypertension, diabetes, metabolic syndrome), associated clinical conditions andtherapeutics, and basic biochemical profile. Student’s t-test and chi-square orFisher exact tests were used. We haveincluded 3.845 patients included from one-day record of 2001physicians. On average, each patient included in the study took about 3 drugsdaily, with a minimum of 1 (statin) and a maximum of 16. The mostfrequent prescribed statin were atorvastatin. Maximum dosis of statins wereused in 14 % of patients. Concomitants drugs metabolized by CYP450 pathway wastaken by 13 % , and statins with this metabolic route were used by75 %. Almost 10 % shown a potential interaction between drugs with metabolicinterferences. More severity muscle adverse effects were associated with. Aacoholintake, visceral obesity, systolic blood pressure, prevalence of hypertension,and poor lipid control. Understandingstatin-induced myopathy is important given the large and expanding number ofeligible patients for statin therapy according with different guidelines oncholesterol management.
EAS-0243. INTER-INDIVIDUAL VARIABILITY IN TRIGLYCERIDE LEVELS AND PLASMA OMEGA-3 INDEX (O3I) AFTER FISH OIL SUPPLEMENTATION H. Cormier 1, *, I. Rudkowska 2, S. Lemieux 1, P. Julien 3, P. Couture 3, M.C. Vohl 1. 1 Institute of Nutrition and Functional Foods, Universite Laval, Quebec City, Canada; 2 Department of Kinesiology, Universite Laval, Quebec City, Canada; 3 Endocrinology and Nephrology, CHU de Quebec Research Center, Quebec City, Canada
* Corresponding author.
qualified as negative responders. A significant association between relative changes of O3I and TG levels was observed only for positive responders (r¼0.25, p¼0.002). Conclusions: There were no defined responses to n-3 PUFA supplementation, revealing the inconsistency in TG response among healthy-overweight subjects after fish oil supplementation. A high degree of interindividual variability in plasma TG response was observed even in the case of a suitable n-3 PUFA incorporation into PPLs after the supplementation suggesting that the heterogeneity in TG response may be, at least partly, attributable to other factors such as genetic variations and gene-environment interactions. EAS-0252. EFFECTS OF FLUVASTATIN VERSUS PROBUCOL ON LIPID ABNORMALITIES IN NON-DIABETIC PATIENTS WITH CHRONIC KIDNEY DISEASE G. Yasuda*, Y. Yamamoto, S. Saka, N. Hirawa. Nephrology and Hypertension, Yokohama City University, Yokohama, Japan
* Corresponding author. Aim: Lipid abnormalities often develop, playing an important role in glomerular injury in patients with chronic kidney disease (CKD), but few medications are available for controlling lipid metabolism in CKD. We examined the effects of fluvastatin,one of the potent statins, on lipid abnormalities in non-diabetic patients with CKD, and compared with those of probucol. Methods: Patients were treated for 26 weeks with either fluvastatin (20 mg/day) or probucol (500 mg/day). Inclusion criteria were estimated glomerular filtration rate<60mL/min/1.73m2, serum low-density lipoprotein (LDL) cholesterol levels>140 mg/dL, triglyceride levels>150 mg/dL, and hemoglobin A1c<6.5%. Lipid parameters were measured before and after treatment. Results: Serum LDL cholesterol decreased significantly (P<0.05) from 179±41 to 123±34 mg/dL in the fluvastatin group (n¼27, aged 64±9 years, men/women: 16/11) and from 176±40 to 127±27 mg/dL in the probucol group (n¼33, 67±10 years, 20/13). Fluvastatin and probucol significantly (P<0.05) decreased triglyceride levels from 255±59 to 172±53 mg/dL and from 229±60 to 161±53 mg/dL. High-density lipoprotein (HDL) cholesterol concentrations did not change (P¼0.49) between 53±19 mg/dL and 51±14 mg/dL in the fluvastatin group, but decreased significantly (P¼0.04) from 54±14 to 45±14 mg/dL in the probucol group. Serum creatinine levels showed no changes (P>0.05) between 2.0±0.7 and 2.2±0.9 mg/dL in the fluvastatin group and between 2.1±0.7 and 2.2±1.0 mg/dL in the probucol group. Conclusions: These results demonstrate that fluvastatin improved LDL cholesterol levels without changing HDL cholesterol levels and renal function. This suggests that fluvastatin is useful for controlling lipid abnormalities in non-diabetic patients with CKD.
Aim: To verify the relationship between plasma triglyceride (TG) levels and Omega-3 Index (O3I) following a 6-wk fish oil supplementation among positive/negative responders.
EAS-0275. STATIN TREATMENT IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION ACCORDING TO LEFT VENTRICULAR SYSTOLIC FUNCTION
Methods: 208 subjects completed a 6-wk supplementation period with 5g/d of fish oil (1.9-2.2g/d of EPA þ 1.1g/d of DHA). Subjects were categorised as positive or negative responders based on their relative change of plasma TG levels after the supplementation. Plasma phospholipid (PPLs) fatty acid (FA) profiles were obtained by gas chromatography. O3I was calculated as the contribution of EPA þ DHA (in % of total FAs) on a 26 FAs spectrum. Results: After the 6-wk supplementation, a significant increase in EPA (þ331.1±214.7%, CV: 0.65) and DHA (þ46.3±27.5%, CV: 0.59) levels in PPLs was observed, in addition to a significant increase of the O3I. However, even in presence of an overall decrease of TG levels (-11.9±25.9%, CV: 2.18), an unpredictable increase was observed for 28.8% of the subjects, thus
S.H. Kim 1, *, H.L. Lee 2, H.L. Kim 1, M.S. IM 1, J.B. Seo 1, W.Y. Chung 1, J.H. Zo 1, M.A. Kim 1, D.J. Choi 3. 1 Internal Medicine Cardiology, Seoul Boramae Hospital, Seoul, Korea; 2 Internal Medicine, Seoul Bukbu Hospital, Seoul, Korea; 3 Internal Medicine Cardiology, Seoul National University Bundang Hospital, Seoul, Korea
* Corresponding author. Aim: Statin decreases low density lipoprotein cholesterol level and prevents atherosclerosis. Although statin may be beneficial for patients with acute myocardial infarction (AMI), statin is not usually prescribed to all patients with AMI. This study was performed to identify different
Abstracts / Atherosclerosis 241 (2015) e149ee229
EAS-0234. ASSOCIATED CONDITIONS WITH STATIN-INDUCED MUSCLE ADVERSE EFFECTS ~ ez-Corte s 2, J.A. Flores 3, J. Rius 4. 1 Lipids Unit, J. Pedro-Botet 1, *, J. Mill an Nún Hospital del Mar, Barcelona, Spain; 2 Internal Medicine, HGU Gregorio ~o n, Madrid, Spain; 3 Endocrinology, Hospital del Mar, Barcelona, Maran Spain; 4 Medical Affairs, Esteve, Barcelona, Spain
* Corresponding author. Theclinical spectrum of statin induced myotoxicity includes clinical symptoms, signs and laboratory findings, fromasymptomatic elevation of CK levels or benign myalgia toa more severe painful myositis and fatal rhabdomyolysis. The aim ofthis study was to describe the severity of muscle injury and associatedconditions related with statin therapy and to identify patients that may have potential interactions withstatins Thismulticenter national study including statin-treated patients of both sexes over18 years of age with on-visit recorded for evaluation including: age, gender,anthropometric parameters, cardiovascular risk factors (dyslipidemia,hypertension, diabetes, metabolic syndrome), associated clinical conditions andtherapeutics, and basic biochemical profile. Student’s t-test and chi-square orFisher exact tests were used. We haveincluded 3.845 patients included from one-day record of 2001physicians. On average, each patient included in the study took about 3 drugsdaily, with a minimum of 1 (statin) and a maximum of 16. The mostfrequent prescribed statin were atorvastatin. Maximum dosis of statins wereused in 14 % of patients. Concomitants drugs metabolized by CYP450 pathway wastaken by 13 % , and statins with this metabolic route were used by75 %. Almost 10 % shown a potential interaction between drugs with metabolicinterferences. More severity muscle adverse effects were associated with. Aacoholintake, visceral obesity, systolic blood pressure, prevalence of hypertension,and poor lipid control. Understandingstatin-induced myopathy is important given the large and expanding number ofeligible patients for statin therapy according with different guidelines oncholesterol management.
EAS-0243. INTER-INDIVIDUAL VARIABILITY IN TRIGLYCERIDE LEVELS AND PLASMA OMEGA-3 INDEX (O3I) AFTER FISH OIL SUPPLEMENTATION H. Cormier 1, *, I. Rudkowska 2, S. Lemieux 1, P. Julien 3, P. Couture 3, M.C. Vohl 1. 1 Institute of Nutrition and Functional Foods, Universite Laval, Quebec City, Canada; 2 Department of Kinesiology, Universite Laval, Quebec City, Canada; 3 Endocrinology and Nephrology, CHU de Quebec Research Center, Quebec City, Canada
* Corresponding author.
qualified as negative responders. A significant association between relative changes of O3I and TG levels was observed only for positive responders (r¼0.25, p¼0.002). Conclusions: There were no defined responses to n-3 PUFA supplementation, revealing the inconsistency in TG response among healthy-overweight subjects after fish oil supplementation. A high degree of interindividual variability in plasma TG response was observed even in the case of a suitable n-3 PUFA incorporation into PPLs after the supplementation suggesting that the heterogeneity in TG response may be, at least partly, attributable to other factors such as genetic variations and gene-environment interactions. EAS-0252. EFFECTS OF FLUVASTATIN VERSUS PROBUCOL ON LIPID ABNORMALITIES IN NON-DIABETIC PATIENTS WITH CHRONIC KIDNEY DISEASE G. Yasuda*, Y. Yamamoto, S. Saka, N. Hirawa. Nephrology and Hypertension, Yokohama City University, Yokohama, Japan
* Corresponding author. Aim: Lipid abnormalities often develop, playing an important role in glomerular injury in patients with chronic kidney disease (CKD), but few medications are available for controlling lipid metabolism in CKD. We examined the effects of fluvastatin,one of the potent statins, on lipid abnormalities in non-diabetic patients with CKD, and compared with those of probucol. Methods: Patients were treated for 26 weeks with either fluvastatin (20 mg/day) or probucol (500 mg/day). Inclusion criteria were estimated glomerular filtration rate<60mL/min/1.73m2, serum low-density lipoprotein (LDL) cholesterol levels>140 mg/dL, triglyceride levels>150 mg/dL, and hemoglobin A1c<6.5%. Lipid parameters were measured before and after treatment. Results: Serum LDL cholesterol decreased significantly (P<0.05) from 179±41 to 123±34 mg/dL in the fluvastatin group (n¼27, aged 64±9 years, men/women: 16/11) and from 176±40 to 127±27 mg/dL in the probucol group (n¼33, 67±10 years, 20/13). Fluvastatin and probucol significantly (P<0.05) decreased triglyceride levels from 255±59 to 172±53 mg/dL and from 229±60 to 161±53 mg/dL. High-density lipoprotein (HDL) cholesterol concentrations did not change (P¼0.49) between 53±19 mg/dL and 51±14 mg/dL in the fluvastatin group, but decreased significantly (P¼0.04) from 54±14 to 45±14 mg/dL in the probucol group. Serum creatinine levels showed no changes (P>0.05) between 2.0±0.7 and 2.2±0.9 mg/dL in the fluvastatin group and between 2.1±0.7 and 2.2±1.0 mg/dL in the probucol group. Conclusions: These results demonstrate that fluvastatin improved LDL cholesterol levels without changing HDL cholesterol levels and renal function. This suggests that fluvastatin is useful for controlling lipid abnormalities in non-diabetic patients with CKD.
Aim: To verify the relationship between plasma triglyceride (TG) levels and Omega-3 Index (O3I) following a 6-wk fish oil supplementation among positive/negative responders.
EAS-0275. STATIN TREATMENT IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION ACCORDING TO LEFT VENTRICULAR SYSTOLIC FUNCTION
Methods: 208 subjects completed a 6-wk supplementation period with 5g/d of fish oil (1.9-2.2g/d of EPA þ 1.1g/d of DHA). Subjects were categorised as positive or negative responders based on their relative change of plasma TG levels after the supplementation. Plasma phospholipid (PPLs) fatty acid (FA) profiles were obtained by gas chromatography. O3I was calculated as the contribution of EPA þ DHA (in % of total FAs) on a 26 FAs spectrum. Results: After the 6-wk supplementation, a significant increase in EPA (þ331.1±214.7%, CV: 0.65) and DHA (þ46.3±27.5%, CV: 0.59) levels in PPLs was observed, in addition to a significant increase of the O3I. However, even in presence of an overall decrease of TG levels (-11.9±25.9%, CV: 2.18), an unpredictable increase was observed for 28.8% of the subjects, thus
S.H. Kim 1, *, H.L. Lee 2, H.L. Kim 1, M.S. IM 1, J.B. Seo 1, W.Y. Chung 1, J.H. Zo 1, M.A. Kim 1, D.J. Choi 3. 1 Internal Medicine Cardiology, Seoul Boramae Hospital, Seoul, Korea; 2 Internal Medicine, Seoul Bukbu Hospital, Seoul, Korea; 3 Internal Medicine Cardiology, Seoul National University Bundang Hospital, Seoul, Korea
* Corresponding author. Aim: Statin decreases low density lipoprotein cholesterol level and prevents atherosclerosis. Although statin may be beneficial for patients with acute myocardial infarction (AMI), statin is not usually prescribed to all patients with AMI. This study was performed to identify different